8 unchanged lines
At the time of the interim DFS analysis, the study demonstrated a statistically significant improvement in DFS in the PD-L1 ≥ 1% TC, Stage II – IIIA patient population.
Efficacy results are presented in Table 2628 and Figure 1.
Table 2628: Efficacy Results from IMpower010 in Patients with Stage II - IIIA NSCLC with PD-L1 expression ≥ 1% TC
| Arm A: TECENTRIQ N = 248 | Arm B: Best Supportive Care N = 228
19 unchanged lines
Among the 205 chemotherapy-naïve patients with stage IV NSCLC with high PD-L1 expression (TC ≥ 50% or IC ≥ 10%) excluding those with EGFR or ALK genomic tumor aberrations, the median age was 65.0 years (range: 33 to 87), and 70% of patients were male. The majority of patients were White (82%) and Asian (17%). Baseline ECOG performance status was 0 (36%) or 1 (64%); 88% were current or previous smokers; and 76% of patients had non-squamous disease while 24% of patients had squamous disease.
The trial demonstrated a statistically significant improvement in OS for patients with high PD-L1 expression (TC ≥50% or IC ≥10%) at the time of the OS interim analysis. There was no statistically significant difference in OS for the other two PD-L1 subgroups (TC ≥5% or IC ≥5%; and TC ≥1% or IC ≥1%) at the interim or final analyses. Efficacy results for patients with NSCLC with high PD-L1 expression are presented in Table 2729 and Figure 2.
Table 2729: Efficacy Results from IMpower110 in Patients with NSCLC with High PD-L1 Expression (TC ≥ 50% or IC ≥ 10%) and without EGFR or ALK Genomic Tumor Aberrations
| Arm A: TECENTRIQ N = 107 | Arm B: Platinum-Based Chemotherapy N = 98
21 unchanged lines
A total of 1202 patients were enrolled across the three arms of whom 1045 were in the ITT-WT subpopulation and 447 were in the tGE-WT subpopulation. The demographic information is limited to the 800 patients enrolled in Arms B and C where efficacy has been demonstrated. The median age was 63 years (range: 31 to 90), and 60% of patients were male. The majority of patients were White (82%), 13% of patients were Asian, 10% were Hispanic, and 2% of patients were Black. Clinical sites in Asia (enrolling 13% of the study population) received paclitaxel at a dose of 175 mg/m2 while the remaining 87% received paclitaxel at a dose of 200 mg/m2. Approximately 14% of patients had liver metastases at baseline, and most patients were current or previous smokers (80%). Baseline ECOG performance status was 0 (43%) or 1 (57%). PD-L1 was TC3 and any IC in 12%, TC0/1/2 and IC2/3 in 13%, and TC0/1/2 and IC0/1 in 75%. The demographics for the 696 patients in the ITT-WT subpopulation were similar to the ITT population except for the absence of patients with EGFR- or ALK- positive NSCLC.
The trial demonstrated a statistically significant improvement in PFS between Arms B and C in both the tGE-WT and ITT-WT subpopulations, but did not demonstrate a significant difference for either subpopulation between Arms A and C based on the final PFS analyses. In the interim analysis of OS, a statistically significant improvement was observed for Arm B compared to Arm C, but not for Arm A compared to Arm C. Efficacy results for the ITT-WT subpopulation are presented in Table 2830 and Figure 3.
Table 2830: Efficacy Results in ITT-WT Population in IMpower150
| Arm C: Bevacizumab, Paclitaxel and Carboplatin | Arm B: TECENTRIQ with Bevacizumab, Paclitaxel, and Carboplatin | Arm A: TECENTRIQ with Paclitaxel, and Carboplatin
29 unchanged lines
A total of 724 patients were enrolled; of these, 681 (94%) were in the ITT-WT population. The median age was 64 years (range: 18 to 86) and 59% were male. The majority of patients were white (90%), 2% of patients were Asian, 5% were Hispanic, and 4% were Black. Baseline ECOG performance status was 0 (41%) or 1 (58%). Most patients were current or previous smokers (90%). PD-L1 tumor expression was TC0/1/2 and IC0/1 in 73%; TC3 and any IC in 14%; and TC0/1/2 and IC2/3 in 13%.
Efficacy results for the ITT-WT population are presented in Table 2931 and Figure 4.
Table 2931: Efficacy Results from IMpower130
| TECENTRIQ with Paclitaxel Protein-Bound and Carboplatin | Paclitaxel Protein-Bound and Carboplatin
26 unchanged lines
Among the first 850 randomized patients, the median age was 64 years (33 to 85 years) and 47% were ≥ 65 years old; 61% were male; 70% were White and 21% were Asian; 15% were current smokers and 67% were former smokers; and 37% had baseline ECOG performance status (PS) of 0 and 63% had a baseline ECOG PS of 1. Nearly all (94%) had metastatic disease, 74% had non-squamous histology, 75% had received only one prior platinum-based chemotherapy regimen, and 55% of patients had PD-L1-expressing tumors.
Efficacy results are presented in Table 3032 and Figure 5.
Table 3032: Efficacy Results in OAK
| TECENTRIQ | Docetaxel
42 unchanged lines
A total of 403 patients were randomized, including 201 to the TECENTRIQ arm and 202 to the chemotherapy alone arm. The median age was 64 years (range 26 to 90) and 65% were male. The majority of patients were White (80%); 17% were Asian, 4% were Hispanic and 1% were Black. Baseline ECOG performance status was 0 (35%) or 1 (65%); 9% of patients had a history of brain metastases, and 97% were current or previous smokers.
Efficacy results are presented in Table 3133 and Figure 6.
Table 3133: Efficacy Results from IMpower133
| TECENTRIQ with Carboplatin and Etoposide | Placebo with Carboplatin and Etoposide
29 unchanged lines
A total of 483 patients were randomized, including 242 to the TECENTRIQ with lurbinectedin arm and 241 to the TECENTRIQ arm. The median age was 66 years (range 35 to 85 years); 63% male; 82% White; 13% Asian; 0.8% were Black or African American; 7% were of Hispanic or Latino ethnicity and 98% were current or previous smokers. Baseline ECOG performance status was 0 (43%) or 1 (57%).
Efficacy results are presented in Table 3234 and Figures 7 and 8.
Table 3234: Efficacy Results from IMforte
| TECENTRIQ with Lurbinectedin N=242 | TECENTRIQ N=241
20 unchanged lines
The major efficacy outcome measures were overall survival (OS) and independent review facility (IRF)-assessed progression free survival (PFS) per RECIST v1.1. Additional efficacy outcome measures were IRF-assessed overall response rate (ORR) per RECIST and mRECIST.
Efficacy results are presented in Table 3335 and Figure 9.
Table 3335: Efficacy Results from IMbrave150
| TECENTRIQ in combination with Bevacizumab (N= 336) | Sorafenib (N=165)
37 unchanged lines
The median age of the study population was 54 years (range: 22-88), 58% of patients were male, 95% were White, a baseline ECOG performance status of 0 (77%) or 1 (23%), 33% had elevated LDH, 94% had metastatic disease, 60% were Stage IV (M1C), 56% had less than three metastatic sites at baseline, 3% had prior treatment for brain metastases, 30% had liver metastases at baseline, and 14% had received prior adjuvant systemic therapy. Based on central testing, 74% were identified as having a V600E mutation, 11% as having V600K mutation, and 1% as having V600D or V600R mutations.
Efficacy results are summarized in Table 3436 and Figure 10. Patients had a median survival follow up time of 18.9 months.
Table 3436: Efficacy Results from IMspire150
| TECENTRIQ + Cobimetinib + Vemurafenib N=256 | Placebo + Cobimetinib + Vemurafenib N=258
21 unchanged lines
A total of 49 patients were enrolled. The median age of patients was 31 years (range: 12-70); 2% of adult patients (n=47) were ≥65 years of age and the pediatric patients (n=2) were ≥12 years of age; 51% of patients were female, 55% White, 29% Black or African American, 10% Asian; 53% had an ECOG performance status of 0 and 45% had an ECOG performance status of 1. All patients had prior surgery for ASPS and 55% received at least one prior line of treatment for ASPS; 55% received radiotherapy and 53% received chemotherapy. Of the patients who reported staging at initial diagnosis, all were Stage IV.
Efficacy results of this study are summarized in Table 3537.
Table 3537: Efficacy Results from Study ML39345
Endpoint | All Patients (N=49)
23 unchanged lines
The major efficacy outcome measure was investigator-assessed disease-free survival (DFS). Overall Survival (OS) was an additional efficacy measure.
The study demonstrated statistically significant improvements in DFS and OS for patients randomized to the TECENTRIQ arm compared with placebo. Efficacy results are presented in Table 3638 and Figures 11 and 12.
Table 3638: Efficacy Results from IMvigor011
| TECENTRIQ N=167 | Placebo N=83
15 unchanged lines
In a pre-specified exploratory analysis based on time from cystectomy to first ctDNA MRD positive sample, the unstratified hazard ratio (HR) for investigator-assessed DFS in the subgroup of patients who had ≤20 weeks to first ctDNA MRD positive sample (n=176), was 0.52 (95% CI: 0.37, 0.74), with median DFS of 8.3 months (95% CI: 6.2, 12.7) in the TECENTRIQ arm and 4.1 months (95% CI: 2.3, 6.2) in the placebo arm. The unstratified HR for OS was 0.63 (95% CI: 0.39, 1.00), with median OS of 32.8 months (95% CI: 24.4, not reached) in the TECENTRIQ arm and 18.2 months (95% CI: 13.1, not reached) in the placebo arm. In the subgroup of patients who had >20 weeks to first ctDNA MRD positive sample (n=74), the unstratified HR for investigator-assessed DFS was 1.04 (95% CI: 0.54, 1.97), with median DFS of 10.5 months (95% CI: 6.9, 20.9) in the TECENTRIQ arm and 10.5 months (95% CI: 6.5, 20.5) in the placebo arm. The unstratified HR for OS was 0.77 (95% CI: 0.30, 1.96); median OS was not reached in either arm (95% CI: 21.1 months, not reached in the TECENTRIQ arm and 18.4 months, not reached in the placebo arm).
14.7 dMMR Colon Cancer
The efficacy of TECENTRIQ in combination with mFOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) was evaluated in ATOMIC/ML39057 (NCT02912559), a multicenter, randomized, open-label, active-controlled study in 711 adults and one pediatric patient with Stage III dMMR colon cancer after a complete (R0) resection of the primary tumor with no evidence of residual lymph node involvement or metastatic disease. Patients were excluded if they had a rectal tumor (tumor must be in the colon); prior chemotherapy, radiation, or drug therapies (with the exception of one cycle of mFOLFOX6); a history of active autoimmune disease; pulmonary disease with hypoxia; grade 2 or higher peripheral motor or sensory neuropathy .Patients were randomized (1:1) to receive one of the following:
TECENTRIQ 840 mg IV once every 2 weeks (the pediatric patient received 10 mg/kg Q2W, until reaching 840 mg) in combination with mFOLFOX6 (oxaliplatin, leucovorin, and fluorouracil) for 6 months (12 cycles), followed by TECENTRIQ IV monotherapy for 6 months (13 cycles), or
mFOLFOX6 every 2 weeks for 6 months (12 cycles).
mFOLFOX6 consisted of oxaliplatin 85 mg/m2, leucovorin 400 mg/m2, and fluorouracil 400 mg/m2 given as a bolus followed by fluorouracil 2400 mg/m2 given as a continuous infusion over 46 hours. Randomization was stratified by nodal status (N1/N1C vs. N2), tumor stage (Tx, T1-T3 vs. T4), and primary tumor location (proximal vs. distal). Study treatment was administered for the planned duration unless disease recurrence or unacceptable toxicity. Tumor assessments per RECIST v1.1 were conducted every 6 months for the first 2 years and then annually for 3 years.
The median age was 64 years (range: 13 to 91 years); 49% were ≥65 years of age, 55% female, 45% male; 85% of patients were White, 7% were Black or African American and 3.1% were Asian; 7% were Hispanic or Latino, 90% not Hispanic or Latino, and 3.3% not reported or unknown.
Baseline ECOG performance status was 0 in 65%, 1 in 33%, and 2 in 1.5%. Overall, 70% of patients had tumor stage Tx, T1-T3 and 30% had T4 tumors. Sixty-four percent of patients had N1/N1C nodal status (1-3 positive nodes) and 36% had N2 nodal status (≥ 4 positive nodes). Tumor location was right-sided in 84% of patients and left-sided in 16% of patients. The major efficacy outcome measure was disease-free survival (DFS) as assessed by the investigator.
Efficacy results are summarized in Table 39 and Figure 13.
Table 39: Efficacy Results from ATOMIC
Endpoint | TECENTRIQ + mFOLFOX6 (n=355) | mFOLFOX6 (n=357)
CI: confidence interval; NR = Not Reached
Disease-Free Survival (DFS) | |
Number of events (%) | 46 (13%) | 81 (23%)
Median DFS (months) (95% CI) | NR | NR
Hazard Ratio (95% CI) | 0.50 (0.35, 0.73)
p-value | 0.0001
Figure 13: Kaplan-Meier Plot of Disease-Free Survival in ATOMIC